导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 2.58% | 1787/4773 |
| 近一周 | -2.30% | 2789/5458 |
| 近一月 | -4.88% | 3130/5421 |
| 近一季 | -5.56% | 2857/5205 |
| 近半年 | -6.53% | 3174/4920 |
| 近一年 | 7.18% | 1496/4361 |
| 近两年 | 68.98% | 1008/2954 |
| 近三年 | 35.01% | 879/2253 |
| 成立以来 | 41.35% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
1.82% 1169/4961 |
18.41% 1382/5312 |
- - |
- - |
| 2025 | 30.31% 1333/4813 |
2.04% 1485/3635 |
1.77% 2163/4076 |
24.40% 1471/4524 |
0.87% 1694/4813 |
| 2024 | 5.96% 1797/3463 |
-2.69% 1409/2808 |
-5.18% 1664/3014 |
15.68% 1655/3129 |
-0.72% 1507/3463 |
| 2023 | -6.11% 813/2656 |
7.55% 555/2280 |
-4.15% 1072/2385 |
-4.63% 1185/2515 |
-4.50% 1062/2655 |
| 2022 | -17.79% 631/2207 |
-13.37% 745/1919 |
3.27% 1182/2016 |
-10.50% 415/2113 |
2.66% 866/2208 |
| 2021 | 16.03% 283/1822 |
-1.78% 540/1255 |
9.27% 570/1330 |
4.62% 331/1466 |
3.34% 449/1822 |
| 2020 | 22.92% 662/1250 |
-4.50% 370/1028 |
16.60% 427/1067 |
6.93% 812/1164 |
3.23% 934/1184 |
| 2019 | 25.67% 596/1092 |
30.49% 244/739 |
-9.81% 694/788 |
0.28% 537/850 |
6.49% 603/918 |
| 2018 | -31.02% 487/834 |
- - |
-13.43% 445/631 |
-7.15% 435/660 |
-12.10% 402/682 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 天弘恒生沪深港创新药精选50ETF | 0.8428 | 28.18% |
| 港股通药 | 0.8930 | 27.53% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.2971 | 26.78% |
| 华富中证港股通创新药指数型发起式C | 1.1445 | 26.30% |
| 万家中证港股通创新药ETF | 1.5973 | 26.27% |
| 景顺长城中证港股通创新药ETF | 1.6587 | 26.20% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2831 | 25.87% |
| 港医疗 | 0.8885 | 25.59% |
| 景顺长城中证港股通创新药ETF联接A | 1.4594 | 25.50% |
| 华富中证港股通创新药指数型发起式A | 1.1526 | 25.42% |
| 南方中证500ETF联接(LOF)C VS. 长安沪深300非周期A(740101) |